Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook
August 21, 2018 4:08 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $200.9 million versus the consensus estimate of $195.76 million.
GUIDANCE:
Myriad Genetics sees Q1 2019 EPS of $0.28-$0.30, versus the consensus of... More



